Andrea M. Woltman, PhD
Assistant Professor

Contact details:
Room L-244

Send an email

Andrea Woltman studied Biomedical Sciences at the University of Leiden, The Netherlands (1993-1998; cum laude). She performed her Ph.D. study at the Department of Nephrology of the Leiden University Medical Center in Leiden with a research visit to Schering-Plough, Dardilly, France. She defended her thesis entitled "Functional modulation of human dendritic cells; immunosuppressive drugs and inflammatory mediators in renal allograft rejection" cum laude in 2002. She continued her research at the Department of Nephrology in Leiden and focussed on dendritic cells as potential tools and targets to prevent renal allograft rejection. In 2005 she received a Veni (ZonMW) to work on the molecular mechanisms regulating human dendritic cell development and survival. In May 2006, she became staff member at the Department of Gastroenterology and Hepatology of the Erasmus MC in Rotterdam, The Netherlands. Together with Andre Boonstra, she is leading the immunological research on viral hepatitis. Her research group aims (1) to determine the immunological factors/processes involved in viral clearance/persistence and response to therapy and (2) to develop an effective immunotherapy to cure chronic viral hepatitis. These research lines are focussed on the function of dendritic cells and their interaction with other cells of the immune sytem.

Selected references:

• Van de Laar L, Coffer PJ, Woltman AM.
  Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy.
  Blood. 2012. 119(15):3383-3393.
• Tjwa ETTL, van Oord GW, Biesta P, Boonstra A, Janssen HLA, Woltman AM.
  Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B.
  J Virology. 2012. 86(8): 4102-4109.
• Van de Laar L, Van den Bosch A, Wierenga ATJ, Janssen HLA, Coffer PJ, Woltman AM.
  Tight control of STAT5 activity determines human CD34-derived interstitial dendritic cell and langerhans cell development.
  J. Immunol. 2011. 186(12):7016-7024
• Tjwa ETTL, Van Oord GW, Hegmans JP, Janssen HLA, Woltman AM.
  Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.
  J. Hepatol. 2011. 54(2): 209-218.
• Woltman AM, Boonstra A, Janssen HLA.
  Dendritic cells in chronic viral hepatitis: victims or guardian angels?
  Gut. 2010. 59: 115-125.
• Stoop JN, Woltman AM, Biesta PJ, Kusters JG, Kuipers EJ, Janssen HL, van der Molen RG (2007).
  Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response.
  Hepatology.46(3):699-705.
• Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C (2003).
  Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression.
  Blood 101, 1439-1445.
  
• Woltman AM, de Fijter JW, Kamerling SW, van Der Kooij SW, Paul LC, Daha MR, van Kooten C (2001).
  Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages.
  Blood. 98(1):174-80.
  
  

Do a PubMed search for references by Andrea Woltman.

Back